Navigation Links
Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013
Date:2/19/2013

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, will hold a conference call on Wednesday, February 20, 2013, at 4:30 p.m. ET to discuss full results for its fourth quarter and year ended December 31, 2012.

While previously expecting to report only preliminary results on this date, the company recently received its annual 'true-up' of OVA1 sales from Quest Diagnostics ahead of schedule. This will allow for complete 2012 results to be issued in a press release prior to the call.

Vermillion's interim CEO Bruce A. Huebner will host the call, followed by a question and answer period.

Date: Wednesday, February 20, 2013
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-909-4761
International: 1-212-231-2934
Conference ID#: 21648726
Webcast: http://edge.media-server.com/m/p/e247e2q2/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call through March 6, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21648726

About Vermillion
Vermillion, Inc. (NASDAQ: VRML)
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... , Aug. 18, 2014 ... of advanced consumer medical devices said that ... was interviewed by CEOLIVE.TV as part of ... entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... Kotak explains to investors the unique advantages ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... 16 NanoSmart™ Pharmaceuticals, Inc., a California corporation developing ... received a Notice of Allowance for a US patent ... "We have taken an approach to targeting tumors that ... CEO of the company. "While most of cancer research ...
... Announces Record Second Quarter 2010 Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia/ -- ... ... --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Aug. 16 NeoStem, Inc. (NYSE Amex: ... company with product and service revenues, global research and ... U.S. adult stem cells, China adult stem cells, and ... quarter 2010. Second Quarter Results ...
Cached Biology Technology:NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 3Nutrastar International Inc. Announces Record Second Quarter 2010 Results 4Nutrastar International Inc. Announces Record Second Quarter 2010 Results 5Nutrastar International Inc. Announces Record Second Quarter 2010 Results 6Nutrastar International Inc. Announces Record Second Quarter 2010 Results 7Nutrastar International Inc. Announces Record Second Quarter 2010 Results 8Nutrastar International Inc. Announces Record Second Quarter 2010 Results 9Nutrastar International Inc. Announces Record Second Quarter 2010 Results 10NeoStem Provides Second Quarter Update 2NeoStem Provides Second Quarter Update 3NeoStem Provides Second Quarter Update 4
(Date:8/20/2014)... In leaves, photosystem 1 (PS1) absorbs light and ... of carbon dioxide to biomass. Photovoltaic devices, mostly ... light but produce electricity. One approach for the ... replacing the semi-conductor with the isolated membrane protein ... isolates a highly stable PS1 from thermophilic cyanobacteria ...
(Date:8/20/2014)... Aug. 20, 2014  The second annual Biometrics ... Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and ... The theme of this year,s event is Mobility ... "Biometrics UnPlugged: Mobility at the Crossroads ...
(Date:8/19/2014)... students, chances of completing introductory biology courses and ... implemented a comprehensive student success program, employing various ... , Through a grant from the Texas Higher ... and Biochemistry embarked on a pilot program focusing ... and "Introductory Biology" for science majors. These two ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... The Press Room will be on the fifth floor of ... the Main Lecture Room, offering free wireless access, the book ... January 6 through Friday, January 8, 7:30 a.m.-5:00 p.m., and ... press is free. Two events are open to the ...
... glioma, the most common primary brain tumor, new findings ... cancer. A UCSF-led team of scientists has identified ... stem cells underly a type of glioma called oligodendroglioma. ... to therapy than other brain tumors such as glioblastoma ...
... the allergic reactions that asthmatics suffer towards a common ... had the mould growing in their own lungs. ... Glenfield Hospital has been published in the December 2010 ... Critical Care Medicine . The team based in ...
Cached Biology News:Joint Mathematics Meetings in New Orleans Jan. 6-9 2Joint Mathematics Meetings in New Orleans Jan. 6-9 3Joint Mathematics Meetings in New Orleans Jan. 6-9 4Joint Mathematics Meetings in New Orleans Jan. 6-9 5Joint Mathematics Meetings in New Orleans Jan. 6-9 6Joint Mathematics Meetings in New Orleans Jan. 6-9 7Cell of origin for brain tumors may predict response to therapy 2Cell of origin for brain tumors may predict response to therapy 3New asthma research breaks the mold 2
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: